China’s CanSino recruits over 20,000 people for Covid vaccine trials

Published December 22, 2020
In this file photo, vials of a Covid-19 vaccine candidate, a recombinant adenovirus vaccine named Ad5-nCoV, co-developed by Chinese biopharmaceutical firm CanSino Biologics Inc and a team led by Chinese military infectious disease expert, are pictured in Wuhan, Hubei province, China. — Reuters
In this file photo, vials of a Covid-19 vaccine candidate, a recombinant adenovirus vaccine named Ad5-nCoV, co-developed by Chinese biopharmaceutical firm CanSino Biologics Inc and a team led by Chinese military infectious disease expert, are pictured in Wuhan, Hubei province, China. — Reuters

BEIJING: China’s CanSino Biologics Inc has recruited over 20,000 participants for late-stage human trials overseas for its coronavirus vaccine, a health official said on Monday.

The candidate, known as Ad5-nCoV or Convidecia, which CanSinoBIO is jointly developing with a research institute backed by the Chinese military, is among the five vaccines China has moved into Phase 3 clinical trials to test their efficacy.

“As for now, the number of recruited participants has exceeded 20,000 people, and the progress is relatively fast,” Zheng Zhongwei, an official at China’s National Health Commission, told a press conference.

Pakistan among states where participants are being listed

Phase 3 trials for CanSinoBIO’s candidate, which are planned to involve 40,000 participants in total, have begun enrolling participants in Pakistan, Russia, Mexico and Chile, the latest clinical trial registration data showed. The candidate also has trials lined up in Argentina and has secured a supply deal with Mexico.

The one-dose vaccine had been given to about 40,000-50,000 people in emergency use since it obtained approval for use in military personnel in June, CanSinoBIO Chief Executive Yu Xuefeng said in an industrial event on Nov 28.

A vaccine developed by Chinese Academy of Medical Sciences could start Phase 3 clinical trial soon, Zheng said on Monday, without specifying where it will be tested.

Published in Dawn, December 22nd, 2020

Opinion

Editorial

Disregarding CCI
Updated 04 Nov, 2024

Disregarding CCI

The failure to regularly convene CCI meetings means that the process of democratic decision-making is falling apart.
Defeating TB
04 Nov, 2024

Defeating TB

CONSIDERING the fact that Pakistan has the fifth highest burden of tuberculosis in the world as per the World Health...
Ceasefire charade
Updated 04 Nov, 2024

Ceasefire charade

The US talks of peace, while simultaneously arming and funding their Israeli allies, are doomed to fail, and are little more than a charade.
Concerning measures
Updated 03 Nov, 2024

Concerning measures

The govt must seek political input and consensus on the changes it is seeking to make and be open about its intentions.
Short-lived relief?
03 Nov, 2024

Short-lived relief?

POLICYMAKERS must be jumping with joy. At the close of the first quarter of FY25, the budget posted a consolidated...
Brisk spread
03 Nov, 2024

Brisk spread

THE surge in polio cases has reached distressing levels with a tally of 45 last reported, after two cases emerged in...